“Health is the greatest gift, contentment the greatest wealth, faithfulness the best relationship.” – Buddha

 

PNA Spotlight: Dr. Aaron Cohen-Gadol

This month the PNA Spotlight focuses on Dr. Aaron Cohen-Gadol, a professor at Indiana University Department of Neurosurgery. He is the director of neurosurgical oncology and its fellowship, and co-director of the Signature Center for Brain and Neurological Tumors. Dr. Cohen-Gadol earned his undergraduate degree from the University
of California at San Diego and attended medical school at the University of Southern California. He then completed his residency training at Mayo Clinic in Rochester, Minnesota. He also completed fellowship training in two subspecialties: epilepsy surgery (Yale University) and skull base/cerebrovascular surgery (University of Arkansas.) In addition, Dr. Cohen holds a Master’s Degree in Clinical Research from Mayo Graduate School and an MBA from Kelley School of Business. His areas of interest include surgical treatment of complex intracranial tumors and vascular lesions.

He is the founder and president of The Neurosurgical Atlas (https://www.neurosurgicalatlas.com), a multimedia resource for neurosurgical techniques. Dr. Cohen-Gadol was kind enough to answer some questions posed by the PNA. His answers follow.

Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support

Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.

Sign up to get dedicated support:

Patients: Sign up for support | Recorlev® (levoketoconazole)

HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)

Have more questions? Call for more support at 1-844-444-RCLV (7258)

PNA Medical Corner: Somatotroph Adenoma in a Young Adult

This month the PNA Medical Corner spotlights an article co-authored by a member of the PNA, Dr. Ursula Kaiser, Chief of the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. The case report looks at early onset excess of growth hormone in the context of a somatotroph adenoma in a young adult.

Link: https://doi.org/10.1210/jcemcr/luad030

Early Onset GH Excess: Somatotroph Adenoma in a Young Adult

Featured News and Updates

The FDA has approved NGENLA (somatrogon-ghla)

The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

See the Press Release here>

News Articles June 2025

News Articles June 2025

New imaging tool to diagnose Cushing’s?

An article in Cushing’s Disease News looks at a study that find that a new form of PET scan, alongside a CT  scans can detect tumors that produce ACTH, common in Cushing’s disease. Read more:

https://cushingsdiseasenews.com/news/imaging-technique-found-accurately-id-cushings-pituitary-tumors/

Exercise and hormonal health

An article in mindbodygreen.com examines the effect of exercise on your hormones. Read more: https://www.mindbodygreen.com/articles/how-high-intensity-exercise-impacts-cortisol-and-other-hormones

Pituitary patient describes afterlife following near-death experience

A story on MSN.com relates the experiences of Brianna Lafferty, a pituitary patient who was clinically dead for 8 minutes. She now works as a transition guide. Read more here:

https://www.msn.com/en-us/health/medical/woman-who-died-for-8-minutes-claims-death-is-an-illusion-as-she-recalls-afterlife/ar-AA1FuWo5

Research Articles

June 2025 Research Articles

Pituitary Tumors

Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.

Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS.Pituitary. 2025 Jun 2;28(3):70. doi: 10.1007/s11102-025-01541-0.

Impulse control disorders in pituitary adenoma: What do we know and what we still don’t know in almost two decades?

Kadioglu P, Glezer A.Pituitary. 2025 Jun 2;28(3):71. doi: 10.1007/s11102-025-01533-0.

Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.

Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS.Pituitary. 2025 Jun 2;28(3):70. doi: 10.1007/s11102-025-01541-0. 

Impulse control disorders in pituitary adenoma: What do we know and what we still don’t know in almost two decades?

Kadioglu P, Glezer A.Pituitary. 2025 Jun 2;28(3):71. doi: 10.1007/s11102-025-01533-0.

Clinico-pathological and molecular characteristics of pediatric-juvenile pituitary neuroendocrine tumors (PitNETs): A mono-institutional series.

Buccoliero AM, Giunti L, Ponticelli A, Innocenti L, Ricci F, Cetica V, Tirinnanzi B, Moscardi S, Stagi S, Sardi I, Mussa F, Genitori L, Scagnet M.Clin Neuropathol. 2025 Jun 2. doi: 10.5414/NP301685. Online ahead of print.

Pituitary Surgery


Use of a Septal Stapler to Secure a Septal Free Mucosal Graft to the Nasoseptal Flap Donor Site Following Endoscopic Endonasal Resection of a Pituitary Adenoma.

Miller JE, Fischer JL, Wang MB.J Neurol Surg Rep. 2025 Apr 23;86(2):e98. doi: 10.1055/a-2531-6140. eCollection 2025 Apr.

Hormonal health

The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial.

Atila C, Camerin SJ, Liechti ME, Christ-Crain M.Endocr Connect. 2025 Jun 1:EC-25-0254. doi: 10.1530/EC-25-0254. Online ahead of print.

Combined pituitary hormone deficiency with a novel GLI2 frameshift variant.

Matsuo Y, Adachi N, Mukai T, Kato S, Kato M, Tanaka H.Pediatr Int. 2025 Jan-Dec;67(1):e70082. doi: 10.1111/ped.70082.PMID: 40457737 No abstract available.

Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study.

Castro S, Ng Yin K, d’Aniello F, Alexander EC, Connolly E, Hughes C, Martin L, Prasad R, Storr HL, Willemsen RH, Dunkel L, Butler G, Howard SR.Hum Reprod Open. 2025 May 13;2025(2):hoaf026. doi: 10.1093/hropen/hoaf026. eCollection 2025.

Long-term pituitary function following transsphenoidal surgery for non-functional pituitary neuroendocrine tumor with apoplexy: a single-center retrospective analysis.

Zou D, Yang Y, Gao R, Ou Y, Luo J, Zhang Z, Yang T, Cheng J.Sci Rep. 2025 Jun 1;15(1):19226. doi: 10.1038/s41598-025-03053-0.

Safety and efficacy of endoscopic vs. microscopic approaches in pituitary adenoma surgery: A systematic review and meta-analysis.

Al-Dardery NM, Khaity A, Soliman Y, Ali MOM, Zedan EM, Muyasarah K, Elfakhrany MD.Neurosurg Rev. 2025 Jun 1;48(1):471. doi: 10.1007/s10143-025-03600-3.

 

Hormonal Health

The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial.

Atila C, Camerin SJ, Liechti ME, Christ-Crain M.Endocr Connect. 2025 Jun 1:EC-25-0254. doi: 10.1530/EC-25-0254. Online ahead of print.

Combined pituitary hormone deficiency with a novel GLI2 frameshift variant.

Matsuo Y, Adachi N, Mukai T, Kato S, Kato M, Tanaka H.Pediatr Int. 2025 Jan-Dec;67(1):e70082. doi: 10.1111/ped.70082.

 

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.